GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Renews GMP certifications for India and Malaysia sites
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The Issue opened on June 18, 2024 and closed on June 21, 2024
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Subscribe To Our Newsletter & Stay Updated
